Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis

Lancet Respiratory Medicine,The - Tập 10 - Trang 937-948 - 2022
Marius M Hoeper1, Krit Dwivedi2, Christine Pausch3, Robert A Lewis2, Karen M Olsson1, Doerte Huscher4, David Pittrow3,5, Ekkehard Grünig6, Gerd Staehler7, Carmine Dario Vizza8, Henning Gall9, Oliver Distler10, Christian Opitz11, John Simon R Gibbs12, Marion Delcroix13, Da-Hee Park1, Hossein Ardeschir Ghofrani9,14, Ralf Ewert15, Harald Kaemmerer16, Hans-Joachim Kabitz17
1Clinic of Respiratory Medicine, Hannover Medical School, member of the German Center of Lung Research (DZL), Germany
2Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital and Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
3GWT-TUD, Epidemiological Centre, Technical University Dresden, Dresden, Germany
4Institute of Biometry and Clinical Epidemiology, and Berlin Insitute of Health, Charité-Universitätsmedizin, Berlin, Germany
5Institute for Clinical Pharmacology, Medical Faculty, Technical University Dresden, Dresden, Germany
6Center for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg, member of the German Center for Lung Research (DZL), Germany
7Lungenklinik Löwenstein, Löwenstein, Germany
8Dipartimento di Scienze Cliniche Internistiche, Anestiologiche e Cardiolohiche, Sapienza, University of Rome, Rome, Italy
9Department of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center, Giessen, Germany
10Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
11Department of Cardiology, DRK Kliniken Berlin Westend, Berlin, Germany
12Department of Cardiology, National Heart & Lung Institute, Imperial College London, London, UK
13Clinical Department of Respiratory Diseases, University Hospitals of Leuven and Laboratory of Respiratory Diseases and Thoracic Surgery, Department of Chronic Diseases and Metabolism, Katholieke Universiteit Leuven University of Leuven, Leuven, Belgium
14Department of Medicine, Imperial College London, London, UK
15Clinic of Internal Medicine, Department of Respiratory Medicine, Universitätsmedizin Greifswald, Greifswald, Germany
16Deutsches Herzzentrum München, Klinik für angeborene Herzfehler und Kinderkardiologie, TU München, Munich, Germany
17Gemeinnützige Krankenhausbetriebsgesellschaft Konstanz, Medizinische Klinik II, Konstanz, Germany

Tài liệu tham khảo

Galiè, 2015, Eur Respir J, 46, 903, 10.1183/13993003.01032-2015 Simonneau, 2019, Haemodynamic definitions and updated clinical classification of pulmonary hypertension, Eur Respir J, 53, 10.1183/13993003.01913-2018 Rich, 1987, Primary pulmonary hypertension. A national prospective study, Ann Intern Med, 107, 216, 10.7326/0003-4819-107-2-216 Ling, 2012, Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland, Am J Respir Crit Care Med, 186, 790, 10.1164/rccm.201203-0383OC Hoeper, 2013, Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry, Int J Cardiol, 168, 871, 10.1016/j.ijcard.2012.10.026 Kylhammar, 2018, A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension, Eur Heart J, 39, 4175, 10.1093/eurheartj/ehx257 Trip, 2013, Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses, Eur Respir J, 42, 1575, 10.1183/09031936.00184412 Lewis, 2020, Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension, Eur Respir J, 55, 10.1183/13993003.00041-2020 Schiess, 2010, Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study, Chest, 138, 1086, 10.1378/chest.09-2962 Hoeper, 2020, Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry, J Heart Lung Transplant, 39, 1435, 10.1016/j.healun.2020.09.011 Hurdman, 2012, ASPIRE registry: assessing the spectrum of pulmonary hypertension identified at a referral centre, Eur Respir J, 39, 945, 10.1183/09031936.00078411 Hoeper, 2016, Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction, JACC Heart Fail, 4, 441, 10.1016/j.jchf.2015.12.016 Dwivedi, 2022, Computed tomography lung parenchymal descriptions in routine radiological reporting have diagnostic and prognostic utility in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with lung disease, ERJ Open Res, 8, 10.1183/23120541.00549-2021 Hoeper, 2021, COMPERA 2.0: a refined 4-strata risk assessment model for pulmonary arterial hypertension, Eur Respir J D'Alonzo, 1991, Survival in patients with primary pulmonary hypertension. Results from a national prospective registry, Ann Intern Med, 115, 343, 10.7326/0003-4819-115-5-343 Nathan, 2019, Pulmonary hypertension in chronic lung disease and hypoxia, Eur Respir J, 53, 10.1183/13993003.01914-2018 Hoeper, 2017, Is there a vanishing pulmonary capillary syndrome?, Lancet Respir Med, 5, 676, 10.1016/S2213-2600(17)30291-6 Seimetz, 2011, Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice, Cell, 147, 293, 10.1016/j.cell.2011.08.035 Barst, 1996, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension, N Engl J Med, 334, 296, 10.1056/NEJM199602013340504 Rubin, 2002, Bosentan therapy for pulmonary arterial hypertension, N Engl J Med, 346, 896, 10.1056/NEJMoa012212 Galiè, 2005, Sildenafil citrate therapy for pulmonary arterial hypertension, N Engl J Med, 353, 2148, 10.1056/NEJMoa050010 Galiè, 2009, Tadalafil therapy for pulmonary arterial hypertension, Circulation, 119, 2894, 10.1161/CIRCULATIONAHA.108.839274 Galiè, 2008, Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2, Circulation, 117, 3010, 10.1161/CIRCULATIONAHA.107.742510 Galiè, 2015, Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension, N Engl J Med, 373, 834, 10.1056/NEJMoa1413687 Ghofrani, 2013, Riociguat for the treatment of pulmonary arterial hypertension, N Engl J Med, 369, 330, 10.1056/NEJMoa1209655 Pulido, 2013, Macitentan and morbidity and mortality in pulmonary arterial hypertension, N Engl J Med, 369, 809, 10.1056/NEJMoa1213917 Sitbon, 2015, Selexipag for the treatment of pulmonary arterial hypertension, N Engl J Med, 373, 2522, 10.1056/NEJMoa1503184 Valentin, 2021, Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs, Eur Respir J, 58, 10.1183/13993003.04066-2020 Montani, 2017, Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study, Lancet Respir Med, 5, 125, 10.1016/S2213-2600(16)30438-6 Eyries, 2020, Familial pulmonary arterial hypertension by KDR heterozygous loss of function, Eur Respir J, 55, 10.1183/13993003.02165-2019
Thông tin
Thông tin xuất bản

Lancet Respiratory Medicine,The

Tập 10

937-948

Thông tin tác giả